劲方医药-B(02595)股价涨超11%,截至发稿涨10.67%,报43.78港元。此前在美国癌症研究协会(AACR)年会上,劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节,研发进度领先,靶向多个大适应症,展现其管线创新与丰富。国投证券指出,劲方医药为全球布局的创新药企,聚焦肿瘤、免疫疾病领域,已形成RAS靶向疗法矩阵,并积极拓展其他“全球新”...
Source Link劲方医药-B(02595)股价涨超11%,截至发稿涨10.67%,报43.78港元。此前在美国癌症研究协会(AACR)年会上,劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节,研发进度领先,靶向多个大适应症,展现其管线创新与丰富。国投证券指出,劲方医药为全球布局的创新药企,聚焦肿瘤、免疫疾病领域,已形成RAS靶向疗法矩阵,并积极拓展其他“全球新”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.